Linda McAllister has joined Toronto-based molecular diagnostics firm Xagenic as chief medical officer.

McAllister previously has worked on the development and launch of molecular technologies at Roche Diagnostics, Celera Diagnostics, and Affymetrix. She most recently was CMO at the prenatal genetic testing company Cellscape, and she was CMO and VP of R&D at Pharmajet. She also was an adjunct clinical professor in the University of California, San Francisco department of medicine from 1992 to 2005, and a research fellow at Stanford University.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: locus linked to non-syndromic hearing loss, phylogenetic relationships of Klebsiella pneumoniae isolates, and more.

In a column at Nature, researcher Fyodor Kondrashov worries about the influence of politics on Russian science.

The term 'epigenetics' is being used by quacks to give them a veneer of science, writes Adam Rutherford at the Observer.

The NIH has issued a preliminary guidance for newborn dried blood spot research.